ЕФЕКТИВНІСТЬ ЛІКУВАННЯ ХВОРИХ З HBEAG (+) МАРКЕРОМ ХРОНІЧНОГО ВІРУСНОГО ГЕПАТИТУ В ПРИ ЗАСТОСУВАННІ АНАЛОГІВ ІНТЕРФЕРОНУ

Список литературы: Література. 1. World Health Organization. Global alert and response:hepatitis B. Available from:http://www.who.int/csr/disease/hepatitis/whocds csrlyo20022/en/index8.html. 2. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe. EASL 2013.. 3. Novac V. Transfusion Medicine: A Viewpoint on the Problem and Perspectives of Development / VL Novak, BO. Kondratskiy // Ukr. journ hematology and transf. - 2012. - N 4 (д). - С. 15-20. 4. Hussain AB, Karamat KA, Anwar M, Kazmi SY, Tariq WU. Correlation of HBV DNA PCR and HBeAg in hepatitis carriers. J Coll Physicians Surg Pak. 2004; 14:18-20. 5. Badur S, Akgun A. Diagnosis of hepatitis B infections and monitoring of treatment. J Clin Virol. 2001; 21: 229-37. 6. Ljunggren KK, Nordenfelt E, Kidd A. Correlation of HBeAg/anti-HBe, ALT levels and HBV DNA PCR results in HBsAg-positive patients. J Med Virol. 1993; 39: 297-302. 7. Alagiozian-Angelova V, Alagiozian D, Antonov K, Kruslev Z. Clinical significance of serum HBeAg and HBV DNA specific values of virus replication in chronic hepatitis B virus infection. Folia Med. 1998; 40:34-41. 8. Smith HM, Lau JY, Davies SE, Daniels HM, Alexander GJ, Williams R. Significance of serum IgM anti-HBc in chronic hepatitis B virus infection. J Med Virol. 1992;36:16-20. 9. Berninger M, Hammer M, Hoyer B, Gerin JL. An assay for the detection of the DNA genome of hepatitis B virus in serum. J Med Virol. 1982; 9: 57-68. 10. Kaplan PM, Gerin JL, Alter HJ. Hepatitis Bspecific DNA polymerase activity during posttransfusion hepatitis. Nature 1974; 249: 762-63. 11. Norden H, Brattstorm C, Magnius L. High frequency of hepatitis B virus DNA in anti-HBe positive sera on longitudinal follow up of the patients with renal transplants with chronic hepatitis Br J Med Virol. 1989; 27: 322-28. 12. Dienes HP, Gerken G, Goeagen B, Heermann K, Gerlich W, Meyer Zum Buschenfelde KH. Analysis of precore DNA sequence and detection of precore antigen in liver specimens from patients with antihepatitis B e positive chronic hepatitis. Hepatology 1995; 21:17. 13. Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, Thomas HC. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2: 588-91. 14. Fiordalisi G, Ghiotto F, Castelnuovo F, Primi D, Cariani E. Analysis of the hepatitis B virus genome and immune response in HBsAg, anti-HBs positive chronic hepatitis. J Hepatol. 1994; 20: 487-93. 15. Miyakawa Y, Okamoto H, Nayumi M. The molecular basis of hepatitis B e antigen (HBeAg)- negativ infections. J Viral Hepat. 1997; 4: 1-8. 16. Liaw YF, Kao JH, Piratvuth T, Chan HLY, Chien RN, Liu CJ. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531–561 [DOI 10.1007/s12072-012-9365-9364. 17. Shi M, Yang ZJ, Wang RS, Zhang H, et al. Rapid quantitation of lamivudine-resistant mutantsin lamivudine treated and untreated patients with chronic hepatitis B virus infection. Clin Chim Acta. 2006;373(1-2):172-5. 18. Terrault NA, Bzowej NH, Chang KM, Hwang JP, et al. American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261-83. 19. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Schall RA, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468–475 20. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–662. 21. Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, Safadi R, Lee SS, Halota W, Goodman Z, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52:886–893. 22. Niro GA, Ippolito AM, Fontana R, Valvano MR, Gioffreda D, Iacobellis A, Merla A, Durazzo M, Lotti G, Di Mauro L, et al. Long-term outcome of hepatitis B virus-related Chronic Hepatitis under protracted nucleos(t)ide analogues. J Viral Hepat. 2013;20:502–509. 23. Kim CH, Um SH, Seo YS, Jung JY, Kim JD, Yim HJ, Keum B, Kim YS, Jeen YT, Lee HS, et al. Prognosis of hepatitis B-related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents. J Gastroenterol Hepatol. 2012;27:1589–1595. 24. Cadranel JF, Lahmek P, Causse X, Bellaiche G, Bettan L, Fontanges T, Medini A, Henrion J, Chousterman M, Condat B, et al. Epidemiology of chronic hepatitis B infection in France: risk factors for significant fibrosis--results of a nationwide survey. Aliment Pharmacol Ther. 2007;26:565–576. 25. Fiordalisi G, Cariani E, Mantero G, Zanetti A, Tanzi E, Chiaramonte M, Primi D. High genomic variability in the Pre-C region of hepatitis B virus in anti-HBe, HBV DNA- positive chronic hepatitis. J Med Virol. 1990; 31: 297-300. 26. Aziz M, Aziz H, Waheed Y, Gill ML.Predictors of Therapeutic Outcome to Nucleotide Reverse Transcriptase Inhibitor in Hepatitis B Patients. Viral Immunol. 2018;31(9):632-638. 27. Vallet-Pichard A, Pol S. Hepatitis B virus treatment beyond the guidelines: special populations and consideration of treatment withdrawal. Ther Adv Gastroenterol. 2014; 7:148-55. 28. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013;58(3):593-608. 29. Kim V, Abreu RM, Nakagawa DM, Baldassare RM, Carrilho FJ, Ono SK. Pegylated interferon alfa for chronic hepatitis B: systematic review and metaanalysis. J Viral Hepat 2016;23:154– 169. doi: 10.1111/jvh.12418. 30. Wong GL, Wong VW, Chan HL. Combination therapy of interferon and nucleotide/ nucleoside analogues for chronic hepatitis B. J Viral Hepat 2014;21: 825–834. doi: 10.1111/jvh.12341. 31. Marcellin P, Ahn SH, Ma X, Caruntu F, Tak WY, Elkashab M, et al. Hbsag loss with tenofovir disoproxil fumarate (TDF) plus peginterferon alfa 2A (PEG) combination therapy in chronic hepatitis B (CHB). Hepatol Int 2015;9:S40. 32. Xie Q, Zhou H, Bai X, Wu S, Chen JJ, Sheng J, et al. A randomized, openlabel clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B “e” antigen-positive chronic hepatitis B. Clin Infect Dis 2014;59:1714– 1723. doi: 10.1093/cid/ciu702. 33. Chi H, Xie Q, Zhang NP, Qi X, Liang C, Guo S, et al. Addition of peginterferon alfa-2b during longterm nucleos(t)ide analogue therapy increases HBeAg seroconversion and HBsAg decline – week 48 results from a multicenter randomized controlled trial (PEGON Study). Hepatology 2014;60:1106A. 34. Ning Q, Han M, Sun Y, Jiang J, Tan D, Hou J, et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). J Hepatol 2014;61:777–784. doi: 10.1016/j.jhep.2014.05.044. 35. Hu P, Jia S, Zhang WH, Gong G, Li Y, Chen X, et al. A multi-center randomized study on the efficacy and safety of switching to peginterferona-2a (40KD) for 48 or 96 weeks in HBeAg positive CHB patients with a prior NUC history for 1 to 3 years: an interim analysis of NEW SWITCH study. Hepatology 2014;60:1273A–1274A. 36. Brouwer WP, Xie Q, Sonneveld MJ, Zhang N, Zhang Q, Tabak F, et al. Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study). Hepatology 2015; 61:1512–1522. doi: 10.1002/hep.27586. 37. Li GJ, Yu YQ, Chen SL, Fan P, Shao LY, Chen JZ, et al. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment. Antimicrob Agents Chemother 2015;59:4121–4128. doi: 10.1128/AAC. 00249-15